DUPIXENT (dupilumab)
ECZEMA AGENTS SYSTEMIC INTERLEUKIN-4 (IL-4RA)ANTAG.MCAB · ATOPIC DERMATITIS ·+10
Sanofi-Aventis U.S.
Drug class
Asthma Tx- Interleukin-4(IL-4) Receptor Alpha Antagonist,MAb
The phrase "Asthma Tx- Interleukin-4(IL-4) Receptor Alpha Antagonist,MAb" is a compendial or formulary classification heading denoting monoclonal antibody therapies targeted against the interleukin-4 receptor alpha subunit for the management of asthma. Read more about Asthma Tx- Interleukin-4(IL-4) Receptor Alpha Antagonist,MAb
3 drugs in this class 1 manufacturers
Drugs in Asthma Tx- Interleukin-4(IL-4) Receptor Alpha Antagonist,MAb
DUPIXENT PEN (dupilumab)
ECZEMA AGENTS SYSTEMIC INTERLEUKIN-4 (IL-4RA)ANTAG.MCAB · ATOPIC DERMATITIS ·+10
Sanofi-Aventis U.S.
DUPIXENT SYRINGE (dupilumab)
ECZEMA AGENTS SYSTEMIC INTERLEUKIN-4 (IL-4RA)ANTAG.MCAB · ATOPIC DERMATITIS ·+10
Sanofi-Aventis U.S.
Filter & compare in the drug finder →
Opens the drug finder with Asthma Tx- Interleukin-4(IL-4) Receptor Alpha Antagonist,MAb preselected. Add indication or manufacturer filters there.
The phrase "Asthma Tx- Interleukin-4(IL-4) Receptor Alpha Antagonist,MAb" is a compendial or formulary classification heading denoting monoclonal antibody therapies targeted against the interleukin-4 receptor alpha subunit for the management of asthma.
Biologics in this category, primarily represented by dupilumab, function by binding to the shared IL-4Ra subunit, thereby blocking dual signaling cascades driven by interleukin-4 and interleukin-13.
By disrupting these downstream type 2 inflammatory pathways, these agents reduce airway inflammation, mucus hypersecretion, and airway hyperresponsiveness.
Clinically, this drug class is indicated as add-on maintenance therapy for moderate-to-severe eosinophilic or oral corticosteroid–dependent asthma, and its members often extend across other type 2 conditions, including atopic dermatitis, chronic rhinosinusitis with nasal polyposis, and eosinophilic esophagitis.
-
fda.gov
The phrase "Asthma Tx- Interleukin-4(IL-4) Receptor Alpha Antagonist,MAb" is a compendial or formulary classification heading denoting monoclonal antibody therapies targeted against the interleukin-4 receptor alpha subunit for the management of asthma Biologics in this category, primarily represented by dupilumab, function by binding to the shared IL-4Rα subunit, thereby blocking dual signaling cascades driven by interleukin-4 and interleukin-13
-
nih.gov
The phrase "Asthma Tx- Interleukin-4(IL-4) Receptor Alpha Antagonist,MAb" is a compendial or formulary classification heading denoting monoclonal antibody therapies targeted against the interleukin-4 receptor alpha subunit for the management of asthma Biologics in this category, primarily represented by dupilumab, function by binding to the shared IL-4Rα subunit, thereby blocking dual signaling cascades driven by interleukin-4 and interleukin-13 By disrupting these downstream type 2 inflammatory...
-
fepblue.org
By disrupting these downstream type 2 inflammatory pathways, these agents reduce airway inflammation, mucus hypersecretion, and airway hyperresponsiveness Clinically, this drug class is indicated as add-on maintenance therapy for moderate-to-severe eosinophilic or oral corticosteroid–dependent asthma, and its members often extend across other type 2 conditions, including atopic dermatitis, chronic rhinosinusitis with nasal polyposis, and eosinophilic esophagitis
-
formulatesearch.com
Clinically, this drug class is indicated as add-on maintenance therapy for moderate-to-severe eosinophilic or oral corticosteroid–dependent asthma, and its members often extend across other type 2 conditions, including atopic dermatitis, chronic rhinosinusitis with nasal polyposis, and eosinophilic esophagitis
Sign in to follow this class
Following a drug class requires a free Physicians Office Resource account.